Published • loading... • Updated
First Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
First Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results
A highly anticipated Phase III clinical trial has delivered mixed results in testing whether a blood-based test for minimal residual disease (MRD) could guide early treatment for colorectal cancer recurrence (CRC). Published in Nature Medicine, the randomized double-blind ALTAIR trial tested whether trifluridine/tipiracil (FTD/TPI) could improve outcomes in patients with resected stage I–IV CRC who tested positive for Natera’s Signatera circulat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
